These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34885067)

  • 21. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma.
    Khor GH; Froemming GR; Zain RB; Abraham MT; Omar E; Tan SK; Tan AC; Vincent-Chong VK; Thong KL
    Int J Med Sci; 2013; 10(12):1727-39. PubMed ID: 24155659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas.
    Perez-Janices N; Blanco-Luquin I; Tuñón MT; Barba-Ramos E; Ibáñez B; Zazpe-Cenoz I; Martinez-Aguillo M; Hernandez B; Martínez-Lopez E; Fernández AF; Mercado MR; Cabada T; Escors D; Megias D; Guerrero-Setas D
    Oncotarget; 2015 Jan; 6(1):368-80. PubMed ID: 25621889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypermethylation of the large tumor suppressor genes in Japanese lung cancer.
    Sasaki H; Hikosaka Y; Kawano O; Yano M; Fujii Y
    Oncol Lett; 2010 Mar; 1(2):303-307. PubMed ID: 22966299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
    Maille E; Brosseau S; Hanoux V; Creveuil C; Danel C; Bergot E; Scherpereel A; Mazières J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Langlais A; Morin F; Levallet G; Zalcman G
    Br J Cancer; 2019 Feb; 120(4):387-397. PubMed ID: 30739911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer.
    Sun W; Zaboli D; Wang H; Liu Y; Arnaoutakis D; Khan T; Khan Z; Koch WM; Califano JA
    Clin Cancer Res; 2012 Feb; 18(4):1082-91. PubMed ID: 22228635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Alterations and Expression Dynamics of LATS1 and LATS2 Genes in Non-Small-Cell Lung Carcinoma.
    Malik SA; Khan MS; Dar M; Hussain MU; Shah MA; Shafi SM; Mudassar S
    Pathol Oncol Res; 2018 Apr; 24(2):207-214. PubMed ID: 28434174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi.
    Helmbold P; Richter AM; Walesch S; Skorokhod A; Marsch WCh; Enk A; Dammann RH
    J Invest Dermatol; 2012 Mar; 132(3 Pt 1):687-94. PubMed ID: 22113481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification.
    Kornegoor R; Moelans CB; Verschuur-Maes AH; Hogenes MCh; de Bruin PC; Oudejans JJ; van Diest PJ
    Breast Cancer Res; 2012 Jul; 14(4):R101. PubMed ID: 22765268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential gene hypermethylation in genital lichen sclerosus and cancer: a comparative study.
    Guerrero-Setas D; Pérez-Janices N; Ojer A; Blanco-Fernandez L; Guarch-Troyas C; Guarch R
    Histopathology; 2013 Nov; 63(5):659-69. PubMed ID: 23998425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Methylation and protein expression of RASSF2 in prostate cancer].
    Liu G; Yin B; Song YS
    Zhonghua Nan Ke Xue; 2013 Feb; 19(2):107-10. PubMed ID: 23441448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular profile of nasopharyngeal carcinoma: analysing tumour suppressor gene promoter hypermethylation by multiplex ligation-dependent probe amplification.
    Ooft ML; van Ipenburg J; van Loo R; de Jong R; Moelans C; Braunius W; de Bree R; van Diest P; Koljenović S; Baatenburg de Jong R; Hardillo J; Willems SM
    J Clin Pathol; 2018 Apr; 71(4):351-359. PubMed ID: 28893862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.
    Castelo-Branco P; Choufani S; Mack S; Gallagher D; Zhang C; Lipman T; Zhukova N; Walker EJ; Martin D; Merino D; Wasserman JD; Elizabeth C; Alon N; Zhang L; Hovestadt V; Kool M; Jones DT; Zadeh G; Croul S; Hawkins C; Hitzler J; Wang JC; Baruchel S; Dirks PB; Malkin D; Pfister S; Taylor MD; Weksberg R; Tabori U
    Lancet Oncol; 2013 May; 14(6):534-42. PubMed ID: 23598174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
    Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
    Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA hypermethylation of tumor suppressor genes RASSF6 and RASSF10 as independent prognostic factors in adult acute lymphoblastic leukemia.
    Younesian S; Shahkarami S; Ghaffari P; Alizadeh S; Mehrasa R; Ghavamzadeh A; Ghaffari SH
    Leuk Res; 2017 Oct; 61():33-38. PubMed ID: 28869817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrantly hypermethylated tumor suppressor genes were identified in oral squamous cell carcinoma (OSCC).
    Kim SY; Han YK; Song JM; Lee CH; Kang K; Yi JM; Park HR
    Clin Epigenetics; 2019 Aug; 11(1):116. PubMed ID: 31405379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of LINE-1 hypomethylation and RASSF1A promoter hypermethylation in serum DNA is a non-invasion prognostic biomarker for early recurrence of hepatocellular carcinoma after curative resection.
    Liu ZJ; Huang Y; Wei L; He JY; Liu QY; Yu XQ; Li ZL; Zhang J; Li B; Sun CJ; Liang WB; Sun AM; Qin Y
    Neoplasma; 2017; 64(5):795-802. PubMed ID: 28592132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activating Hippo Pathway via Rassf1 by Ursolic Acid Suppresses the Tumorigenesis of Gastric Cancer.
    Kim SH; Jin H; Meng RY; Kim DY; Liu YC; Chai OH; Park BH; Kim SM
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comprehensive evaluation of Hippo pathway silencing in sarcomas.
    Merritt NM; Fullenkamp CA; Hall SL; Qian Q; Desai C; Thomason J; Lambertz AM; Dupuy AJ; Darbro B; Tanas MR
    Oncotarget; 2018 Aug; 9(60):31620-31636. PubMed ID: 30167083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypermethylation of promoter region of LATS1--a CDK interacting protein in oral squamous cell carcinomas--a pilot study in India.
    Reddy VR; Annamalai T; Narayanan V; Ramanathan A
    Asian Pac J Cancer Prev; 2015; 16(4):1599-603. PubMed ID: 25743838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.